RxDoctor Payments Data

Saadi Siddiqi, DO

Interventional Cardiology · Oak Ridge, TNNPI 1396944575

Payments from drug & device makers

$801in general payments, 2019–2025

Across 60 payments — averaging $13.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$424
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$124
  • Abbott$71
  • Johnson & Johnson$60
  • Pfizer$29
  • E.r. Squibb & Sons, L.L.C.$26
  • plus $66 from 4 others

What the payments were for

  • Food & beverage$75594%
  • Education$466%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$801 in reported general payments places this provider in the 10th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$184,970
Medicare patients
2,122
Services billed
4,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban308$304,705
EntrestoSacubitril/Valsartan144$155,515
XareltoRivaroxaban53$55,933
Repatha SyringeEvolocumab36$30,482
Repatha SureclickEvolocumab26$25,297
VascepaIcosapent Ethyl19$11,296
BrilintaTicagrelor12$8,699
Icosapent Ethyl14$8,126
Ranolazine ErRanolazine17$6,718
Metoprolol Succinate363$4,744
Atorvastatin Calcium378$3,570
Flecainide Acetate44$1,975
Rosuvastatin Calcium167$1,676
Metoprolol Tartrate207$1,664
Spironolactone161$1,165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$304,705308 claims
NovartisEntresto$424$155,515144 claims
Johnson & JohnsonXarelto$60$55,93353 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Oak Ridge

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →